Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02534376 · ClinicalTrials.gov registry record · Early Phase 1
Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal
A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 63
- Enrollment target
NCT02534376 is a Early Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 63 participants.
The verdict
NCT02534376, a Early Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
There is evidence in human studies as well as animal studies that treatments to lower cholesterol can reduce the risk of dying from prostate cancer.To decide if cholesterol-lowering therapy can slow the growth of prostate cancer, the investigators would like to lower cholesterol prior to surgery and then measure the growth of prostate cancers cells when the prostate has been removed. The investigators will use the combination of two drugs that is approved by the U.S. Food and Drug Administration to lower cholesterol. The drug combination is commercially available with a doctor's prescription and sold as Vytorin®. It is known that maximal cholesterol-lower effects are seen after 2 weeks of treatment with Vytorin®. Therefore, study patients receive at least 2 weeks, but no more than 6 weeks of Vytorin® prior to surgery.
Interventions
- DRUG ezetimibe 10mg-simvastatin 40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02534376
The ClinicalTrials.gov registry entry for NCT02534376 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ezetimibe 10mg-simvastatin 40mg is the first listed.
NCT02534376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02534376 about?
NCT02534376 is a clinical study titled "Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal". There is evidence in human studies as well as animal studies that treatments to lower cholesterol can reduce the risk of dying from prostate cancer.To decide if cholesterol-lowering therapy can slow the growth of prostate cancer, the investigators would like to lower cholesterol prior to surgery and...
What is the current status of trial NCT02534376?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 63 participants. The study started on 2015-09. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT02534376?
The interventions under investigation include: ezetimibe 10mg-simvastatin 40mg (DRUG).
Who is sponsoring clinical trial NCT02534376?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.